Richard E. Stafford

TL;DR: There is a dose-dependent immunological threshold for establishing high-level protection against malaria that can be achieved with IV administration of a vaccine that is safe and meets regulatory standards.

TL;DR: The results suggest that intravenous administration of this vaccine will lead to the prevention of infection with Plasmodium falciparum malaria and suboptimally immunogenic and protective.

TL;DR: PfSPZ-CVac is a highly efficacious vaccine candidate that could be used for combination mass drug administration and a mass vaccination program approach to eliminate malaria from geographically defined areas when able to optimize the immunization regimen.

TL;DR: Efforts are now focused on how best to achieve submission of a successful Biologics License Application and introduce the vaccine to the primary target population of African children in the shortest possible period of time.

TL;DR: It is suggested that PfSPZ Vaccine conferred durable protection to malaria through long-lived tissue-resident T cells and that administration of higher doses may further enhance protection.